Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents

Journal of Pediatric Endocrinology and Metabolism

Volumn 27, Issue 11-12, 2014, Pages 1175-1179

  Sopher, Aviva B ^a   Grigoriev, Galina ^a   Laura, Diana ^a   Cameo, Tamara ^a   Lerner, Jodi P ^a   Chang, R Jeffrey ^b   Mcmahon, Donald J ^a   Oberfield, Sharon E ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adolescent health; anti Mullerian hormone; polycystic ovary syndrome

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; MUELLERIAN INHIBITING FACTOR; TESTOSTERONE;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; NATIONAL HEALTH ORGANIZATION; ORGAN SIZE; OVARY; OVARY POLYCYSTIC DISEASE; PREDICTIVE VALUE;

EID: 84964292339     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2014-0128     Document Type: Article

References (25)

1. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012; 97: 28-38
2. Azziz R, Carmina E, Dewilly D, Diamanti-Kandarakis E, Excobar-Morreal HF, et al. The androgen excess and PCOS Society for polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-88
3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston, MA: Blackwell Scientific Publications, 1992: 377-84
4. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203: 201.e1-5
5. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74
6. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
7. Brown M, Park AS, Shayya RF, Wolfson T, Su HI, et al. Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls. J Magn Reson Imaging 2013; 38: 689-93
8. Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, et al. Serum anti-Mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab 2010; 95: 1786-92
9. Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005; 84: 938-44
10. Pigny P, Merlen E, Yann R, Cortet-Rudelli C, Decanter C, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88: 5957-62
11. Eilertsen TB, Vanky E, Carlsen SM. Anti-mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Human Reprod 2012; 27: 2494-502
12. Pawelczak M, Kenigsberg L, Milla S, Liu Y, Shah B. Elevated serum anti-mullerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab 2012; 25: 983-9
13. ACOG Committee Opinion. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol 2006; 108: 1323-8
14. Armengaud J, Charkaluk M, Trivin C, Tardy V, Breat G, et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009; 94: 2835-40
15. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 2002: 11 246: 1-27
16. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-7
17. Rao CR. Linear statistical inference. New York: Wiley, 1973
18. Villarroel C, Merino PM, Lopez P, Eyzaguirre FC, Van Velzen A, et al. Polycystic morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011; 26: 2861-8
19. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, et al. Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012; 98: 242-9
20. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26: 3123-9
21. Casadei L, Madrigale A, Puca F, Manicuti C, Emidi E, et al. The role of serum anti-Mullerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol 2013; 29: 545-50
22. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010; 94: 1118-21
23. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-Analysis of extracted data. J Clin Endocrinol Metab 2013; 98: 3332-40
24. Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010; 95: 5003-10
25. Grynberg M, Pierre A, Rey R, Leclerc A, Arouche N, et al. Differential regulation of ovarian anti-Mullerian hormone (AMH) by estradiol through-And β-estrogen receptors. J Clin Endocrinol Metab 2012; 97: E1649-57